Gender differences in the effect of tobacco use on brain phosphocreatine levels in methamphetamine-dependent subjects

References

• Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse. Am Fam Physician 2007;76:1169–1174
   PubMed Web of Science ®Google Scholar
• Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, Barr AM. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend 2013;129:167–179
   PubMed Web of Science ®Google Scholar
• Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, Lecomte T. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 2006;31:301–313
   PubMed Web of Science ®Google Scholar
• Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 2001;36:1–22
   PubMed Web of Science ®Google Scholar
• Kita T, Miyazaki I, Asanuma M, Takeshima M, Wagner GC. Dopamine-induced behavioral changes and oxidative stress in methamphetamine-induced neurotoxicity. Int Rev Neurobiol 2009;88:43–64
   PubMed Web of Science ®Google Scholar
• Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001;158:377–382
   PubMed Web of Science ®Google Scholar
• Cadet JL, Krasnova IN. Molecular bases of methamphetamine-induced neurodegeneration. Int Rev Neurobiol 2009;88:101–119
   PubMed Web of Science ®Google Scholar
• Friedman SD, Castaneda E, Hodge GK. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 1998;61:35–44
   PubMedGoogle Scholar
• Salo R, Fassbender C. Structural, functional and spectroscopic MRI studies of methamphetamine addiction. Current Top Behav Neurosci 2012;11:321–364
   Google Scholar
• Sung YH, Cho SC, Hwang J, Kim SJ, Kim H, Bae S, Kim N, et al. Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: a proton magnetic resonance spectroscopy study. Drug Alcohol Depend 2007;88:28–35
   Google Scholar
• Sung YH, Yurgelun-Todd DA, Shi XF, Kondo DG, Lundberg KJ, McGlade EC, Hellem TL, et al. Decreased frontal lobe phosphocreatine levels in methamphetamine users. Drug Alcohol Depend 2013;129:102–109
   Google Scholar
• Rose ME, Grant JE. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry 2008;20:145–155
   PubMed Web of Science ®Google Scholar
• Weinberger AH, Sofuoglu M. The impact of cigarette smoking on stimulant addiction. Am J Drug Alcohol Abuse 2009;35:12–17
   PubMed Web of Science ®Google Scholar
• Yen CF, Chong MY. Comorbid psychiatric disorders, sex, and methamphetamine use in adolescents: a case-control study. Compr Psychiatry 2006;47:215–220
   PubMed Web of Science ®Google Scholar
• Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer 2012;131:2724–2732
   PubMed Web of Science ®Google Scholar
• Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004;43:1731–1737
   PubMed Web of Science ®Google Scholar
• Starr JM, Deary IJ, Fox HC, Whalley LJ. Smoking and cognitive change from age 11 to 66 years: a confirmatory investigation. Addict Behav 2007;32:63–68
   PubMed Web of Science ®Google Scholar
• Richards M, Jarvis MJ, Thompson N, Wadsworth ME. Cigarette smoking and cognitive decline in midlife: evidence from a prospective birth cohort study. Am J Public Health 2003;93:994–998
   PubMed Web of Science ®Google Scholar
• Ott A, Andersen K, Dewey ME, Letenneur L, Brayne C, Copeland JR, Dartigues JF, et al. Effect of smoking on global cognitive function in nondemented elderly. Neurology 2004;62:920–924
   PubMed Web of Science ®Google Scholar
• Mudo G, Belluardo N, Fuxe K. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm 2007;114:135–147
   Google Scholar
• Evans DE, Drobes DJ. Nicotine self-medication of cognitive-attentional processing. Addict Biol 2009;14:32–42
   Google Scholar
• Picciotto MR, Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Front Biosci 2008;13:492–504
   PubMed Web of Science ®Google Scholar
• Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD. Parkinson’s disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002;155:732–738
   PubMed Web of Science ®Google Scholar
• Morens DM, Grandinetti A, Davis JW, Ross GW, White LR, Reed D. Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson’s disease. Am J Epidemiol 1996;144:400–404
   PubMed Web of Science ®Google Scholar
• Di CG, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274–5278
   PubMed Web of Science ®Google Scholar
• Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996;379:733–736
   PubMed Web of Science ®Google Scholar
• O’Neill AB, Morgan SJ, Brioni JD. Histological and behavioral protection by (-)-nicotine against quinolinic acid-induced neurodegeneration in the hippocampus. Neurobiol Learn Mem 1998;69:46–64
   Google Scholar
• Shimohama S, Greenwald DL, Shafron DH, Akaika A, Maeda T, Kaneko S, Kimura J, et al. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res 1998;779:359–363
   PubMed Web of Science ®Google Scholar
• Anker JJ, Carroll ME. Females are more vulnerable to drug abuse than males: evidence from preclinical studies and the role of ovarian hormones. Curr Topics Behav Neurosci 2011;8:73–96
   PubMedGoogle Scholar
• Carroll ME, Lynch WJ, Roth ME, Morgan AD, Cosgrove KP. Sex and estrogen influence drug abuse. Trends Pharmacolog Sci 2004;25:273–279
   PubMed Web of Science ®Google Scholar
• Dluzen DE, Liu B. Gender differences in methamphetamine use and responses: a review. Gender Medicine 2008;5:24–35
   PubMed Web of Science ®Google Scholar
• Hser YI, Evans E, Huang YC. Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abuse Treat 2005;28:77–85
   PubMed Web of Science ®Google Scholar
• Kalechstein AD, Newton TF, Longshore D, Anglin MD, van Gorp WG, Gawin FH. Psychiatric comorbidity of methamphetamine dependence in a forensic sample. J Neuropsychiatry Clin Neurosci 2000;12:480–484
   PubMed Web of Science ®Google Scholar
• Hall SM, Munoz RF, Reus VI, Sees KL. Nicotine, negative affect, and depression. J Consult Clin Psychol 1993;61:761–767
   PubMed Web of Science ®Google Scholar
• Murphy JM, Horton NJ, Monson RR, Laird NM, Sobol AM, Leighton AH. Cigarette smoking in relation to depression: historical trends from the Stirling County Study. Am J Psychiatry 2003;160:1663–1669
   PubMed Web of Science ®Google Scholar
• Killen JD, Fortmann SP, Schatzberg A, Hayward C, Varady A. Onset of major depression during treatment for nicotine dependence. Addictive Behav 2003;28:461–470
   PubMed Web of Science ®Google Scholar
• Levine MD, Marcus MD, Perkins KA. A history of depression and smoking cessation outcomes among women concerned about post-cessation weight gain. Nicotine Tob Res 2003;5:69–76
   PubMed Web of Science ®Google Scholar
• Smith SS, Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Jamerson B, et al. Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine Tob Res 2003;5:99–109
   PubMed Web of Science ®Google Scholar
• Pomerleau CS, Brouwer RJ, Pomerleau OF. Emergence of depression during early abstinence in depressed and non-depressed women smokers. J Addict Dis 2001;20:73–80
   PubMed Web of Science ®Google Scholar
• Kapelewski CH, Vandenbergh DJ, Klein LC. Effect of the monoamine oxidase inhibition on rewarding effects of nicotine in rodents. Curr Drug Abuse Rev 2011;4:110–121
   Google Scholar
• Yu PH, Boulton AA. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci 1987;41:675–682
   PubMed Web of Science ®Google Scholar
• Carr LA, Basham JK. Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain. Life Sci 1991;48:1173–1177
   PubMedGoogle Scholar
• Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M, Stinus L. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J Neuroscience 2005;25:8593–8600
   PubMed Web of Science ®Google Scholar
• Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 1996;93:14065–14069
   PubMed Web of Science ®Google Scholar
• Leroy C, Bragulat V, Berlin I, Gregoire MC, Bottlaender M, Roumenov D, Dolle F, et al. Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone. J Clinl Psychopharmacol 2009;29:86–88
   PubMedGoogle Scholar
• Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008;13:855–870
   PubMed Web of Science ®Google Scholar
• Jeong EK, Sung YH, Kim SE, Zuo C, Shi X, Mellon EA, Renshaw PF. Measurement of creatine kinase reaction rate in human brain using magnetization transfer image-selected in vivo spectroscopy (MT-ISIS) and a volume (3)(1)P/(1)H radiofrequency coil in a clinical 3-T MRI system. NMR Biomed 2011;24:765–770
   Google Scholar
• Wallimann T, Dolder M, Schlattner U, Eder M, Hornemann T, O’Gorman E, Ruck A, Brdiczka D. Some new aspects of creatine kinase (CK): compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology. BioFactors 1998;8:229–234
   PubMed Web of Science ®Google Scholar
• Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR. Functions and effects of creatine in the central nervous system. Brain Res Bull 2008;76:329–343
   PubMed Web of Science ®Google Scholar
• Mochel F, Durant B, Meng X, O’Callaghan J, Yu H, Brouillet E, Wheeler VC, et al. Early alterations of brain cellular energy homeostasis in Huntington disease models. J Biolog Chem 2012;287:1361–1370
   PubMed Web of Science ®Google Scholar
• Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, et al. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 2004;23(Suppl. 1):S208–S219
   PubMed Web of Science ®Google Scholar
• Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35–43
   PubMed Web of Science ®Google Scholar
• Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de Beer R, Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. Magma 2001;12:141–152
   PubMedGoogle Scholar
• Blumberg RM, Taylor DL, Yue X, Aguan K, McKenzie J, Cady EB, Weiner CP, et al. Increased nitric oxide synthesis is not involved in delayed cerebral energy failure following focal hypoxic-ischemic injury to the developing brain. Pediatric Res 1999;46:224–231
   PubMed Web of Science ®Google Scholar
• Royall RM. Model robust confidence intervals using maximum likelihood estimators. Int Statistical Rev 1986;54:221–226
   Web of Science ®Google Scholar
• Lee PN. Smoking and Alzheimer’s disease: a review of the epidemiological evidence. Neuroepidemiology 1994;13:131–144
   PubMed Web of Science ®Google Scholar
• Van Duijn CM, Clayton DG, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, et al. Interaction between genetic and environmental risk factors for Alzheimer’s disease: a reanalysis of case-control studies. EURODEM Risk Factors Research Group. Genet Epidemiol 1994;11:539–551
   PubMed Web of Science ®Google Scholar
• Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997;42:159–163
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhao B. Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Br J Pharmacol 2004;141:746–754
   PubMed Web of Science ®Google Scholar
• Zamani MR, Allen YS, Owen GP, Gray JA. Nicotine modulates the neurotoxic effect of beta-amyloid protein(25–35) in hippocampal cultures. Neuroreport 1997;8:513–517
   PubMedGoogle Scholar
• Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa K, Sawada H, et al. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson’s disease models. J Neurosci Res 2009;87:576–585
   Google Scholar
• Pauly JR, Charriez CM, Guseva MV, Scheff SW. Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease. An NY Acad Sci 2004;1035:316–334
   Google Scholar
• Callaghan RC, Cunningham JK, Sykes J, Kish SJ. Increased risk of Parkinson’s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 2012;120:35–40
   PubMed Web of Science ®Google Scholar
• Callaghan RC, Cunningham JK, Sajeev G, Kish SJ. Incidence of Parkinson’s disease among hospital patients with methamphetamine-use disorders. Mov Disord 2010;25:2333–2339
   Google Scholar
• Behl C, Skutella T, Lezoualc’h F, Post A, Widmann M, Newton CJ, Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997;51:535–541
   PubMed Web of Science ®Google Scholar
• Spence RD, Voskuhl RR. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front Neuroendocrinol 2012;33:105–115
   PubMed Web of Science ®Google Scholar
• Guan ZZ, Yu WF, Nordberg A. Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells. Neurochem Int 2003;43:243–249
   PubMed Web of Science ®Google Scholar
• Cormier A, Morin C, Zini R, Tillement JP, Lagrue G. In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation. Brain Res 2001;900:72–79
   PubMed Web of Science ®Google Scholar
• Alzoubi KH, Aleisa AM, Gerges NZ, Alkadhi KA. Nicotine reverses adult-onset hypothyroidism-induced impairment of learning and memory: behavioral and electrophysiological studies. J Neurosci Res 2006;84:944–953
   PubMed Web of Science ®Google Scholar
• Morley JE, Shafer RB, Elson MK, Slag MF, Raleigh MJ, Brammer GL, Yuwiler A, Hershman JM. Amphetamine-induced hyperthyroxinemia. Ann Intern Med 1980;93:707–709
   PubMed Web of Science ®Google Scholar
• Manberg PJ, Nemeroff CB, Prange AJ Jr. Thyrotropin-releasing hormone and amphetamine: a comparison of pharmacological profiles in animals. Prog Neuropsychopharmacol 1979;3:303–314
   Google Scholar
• Kato T, Takahashi S, Shioiri T, Inubushi T. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affective Disord 1992;26:223–230
   PubMed Web of Science ®Google Scholar
• Gilbert DG. Depression, smoking, and nicotine: toward a bioinformational situation by trait model. Drug Develop Res 1996;38:267–277
   Google Scholar
• Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED, Shields PG. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol 1998;17:56–62
   PubMed Web of Science ®Google Scholar
• Laucht M, Becker K, Frank J, Schmidt MH, Esser G, Treutlein J, Skowronek MH, Schumann G. Genetic variation in dopamine pathways differentially associated with smoking progression in adolescence. J Am Acad Child Adolesc Psychiatry 2008;47:673–681
   PubMed Web of Science ®Google Scholar
• Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 2006;1762:164–180
   PubMed Web of Science ®Google Scholar
• Chan P, Di MDA, Luo JJ, DeLanney LE, Irwin I, Langston JW. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J Neurochem 1994;62:2484–2487
   Google Scholar
• Walsh B, Tonkonogi M, Soderlund K, Hultman E, Saks V, Sahlin K. The role of phosphorylcreatine and creatine in the regulation of mitochondrial respiration in human skeletal muscle. J Physiol 2001;537(Pt 3):971–978
   Google Scholar
• Rambo LM, Ribeiro LR, Della-Pace ID, Stamm DN, da RGR, Prigol M, Pinton S, et al. Acute creatine administration improves mitochondrial membrane potential and protects against pentylenetetrazol-induced seizures. Amino Acids 2013;44:857–868
   Google Scholar
• Li T, Wang N, Zhao M. Neuroprotective effect of phosphocreatine on focal cerebral ischemia-reperfusion injury. J Biomed Biotechnol 2012;2012:168756
   Google Scholar
• Barbiroli B, Iotti S, Cortelli P, Martinelli P, Lodi R, Carelli V, Montagna P. Low brain intracellular free magnesium in mitochondrial cytopathies. J Cerebral Blood Flow Metabol 1999;19:528–532
   Google Scholar
• Kondo DG, Sung YH, Hellem TL, Fiedler KK, Shi X, Jeong EK, Renshaw PF. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J Affective Disord 2011;135:354–361
   Google Scholar
• Lyoo IK, Kong SW, Sung SM, Hirashima F, Parow A, Hennen J, Cohen BM, Renshaw PF. Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res 2003;123:87–100
   PubMed Web of Science ®Google Scholar
• Royes LF, Fighera MR, Furian AF, Oliveira MS, Myskiw JC, Fiorenza NG, Petry JC, et al. Effectiveness of creatine monohydrate on seizures and oxidative damage induced by methylmalonate. Pharmacol Biochem Behav 2006;83:136–144
   PubMed Web of Science ®Google Scholar
• Becker JB, Hu M. Sex differences in drug abuse. Front Neuroendocrinol 2008;29:36–47
   PubMed Web of Science ®Google Scholar
• Fattore L, Altea S, Fratta W. Sex differences in drug addiction: a review of animal and human studies. Womens Health (Lond Engl) 2008;4:51–65
   PubMedGoogle Scholar
• Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend 2004;74:265–272
   PubMed Web of Science ®Google Scholar
• Terner JM, de WH. Menstrual cycle phase and responses to drugs of abuse in humans. Drug Alcohol Depend 2006;84:1–13
   PubMed Web of Science ®Google Scholar
• Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology 2001;154:161–168
   PubMed Web of Science ®Google Scholar
• Becker JB, Molenda H, Hummer DL. Gender differences in the behavioral responses to cocaine and amphetamine. Implications for mechanisms mediating gender differences in drug abuse. Ann NY Acad Sci 2001;937:172–187
   PubMedGoogle Scholar
• Dluzen DE, McDermott JL. Estrogen, testosterone, and methamphetamine toxicity. Ann NY Acad Sci 2006;1074:282–294
   PubMed Web of Science ®Google Scholar
• Ricaurte GA, Schuster CR, Seiden LS. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 1980;193:153–163
   PubMed Web of Science ®Google Scholar
• Cass WA. Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. J Pharmacol Experim Therapeut 1997;280:105–113
   Google Scholar
• Haughey HM, Fleckenstein AE, Hanson GR. Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. J Neurochem 1999;72:661–668
   Google Scholar
• Wallace TL, Gudelsky GA, Vorhees CV. Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci 1999;19:9141–9148
   PubMed Web of Science ®Google Scholar
• Thrash B, Thiruchelvan K, Ahuja M, Suppiramaniam V, Dhanasekaran M. Methamphetamine-induced neurotoxicity: the road to Parkinson’s disease. Pharmacol Rep 2009;61:966–977
   PubMed Web of Science ®Google Scholar